Department of Pharmacology & Toxicology

Norma C. Adragna, Ph.D., Interim Chair

Andrea Hoffmann, Ph.D.


Andrea Hoffmann, Ph.D.

Research Assistant Professor

Campus Address: 053 LAR
Phone: (937) 775-4021
Fax: (937) 775-7221


M.S. (1998), Universität des Saarland, Saarbrücken, Germany
Ph.D. (2004), Wright State University, Dayton, OH
Postdoctoral (2005-2006), Wright State University, Dayton, OH

Research Interests
  • Toxicology — Dermal, behavioral, immunological, cardiovascular, and nanoparticles
  • Role of Selective Angiotensin II AT2 Receptor Activation in the Prevention of Keloid Scarring (DAGMEC) — Keloids are benign dermal scars that are characterized by enhanced fibroblast proliferation, increased extra-cellular matrix (ECM) deposition and microvascular occlusion. The existence of AngII responsive receptors in normal and keloid fibroblasts suggest that selective targeting of the angiotensinergic system might offer a means in the prevention of keloid scarring. Our objective is that modulation of the angiotensinergic system through selective AT2 receptor signaling activation is able to reduce the progression of keloid scarring through a reduction in cell proliferation activity and activation of apoptotic signaling. This study compares normal and keloid fibroblasts following selective AT2 receptor activation using Western-blotting and assays for cell proliferation and apoptosis, as well as light- and confocal microscopy.
  • Characterization of Selective AT2 Receptor Activation in the Prevention of Melanoma Formation (Wright State Surgery Department Support Grant) — Malignant melanoma formation is characterized by the incidence of DNA damage within melanocytes during epidermal injury such as photoageing, thermal burns or mechanical trauma. The associated hyperproliferation and subsequent metastasis of tumorigenic melanocytes is highly dependent on the proximity of supplying blood vessels. Consequently, the inhibition of angiogenesis has been suggested to act inhibitory on tumor growth. Recently, angiotensin II type AT1 and AT2 receptors have become of major interest in the regulation of vessel growth. In contrast to the AT1 receptor suggested promotion of tumor-associated angiogenesis and proliferation, the AT2 receptor is thought to counteract AT1 receptor-dependent responses. Our objective is to identify if selective activation of AT2 receptor signaling is able to prevent melanoma associated hyperproliferation and angiogenesis thereby inhibiting the progression of melanoma formation. This study compares B16-F1 mouse melanoma cell growth over a four week time period in C57BL/6 mice in presence or absence of selective AT2 receptor activation regarding tumor extension, capillary density and tumorigenic potential.
Selected Publications

Hoffmann, A., J. L. Hoying, and R. Simman. Role of Hyaluronic Acid Treatment in the Prevention of Keloid Formation. College of Certified Wound Specialists ejournal Nov/Dec, Issue 1, 2006.

Chen, Y., H. Chen, A. Hoffmann, D. R. Cool, D. I. Diz, M. C. Chappell, A. Chen and M. Morris. Adenovirus Mediated Small Interference RNA for In Vivo Silencing of Angiotensin AT1a Receptors in Mouse Brain. Hypertension 47:230-7, 2006. [Abstract]

Hoffmann, A. and D. R. Cool. Characterization of Two Polyclonal Peptide Antibodies That Recognize the Carboxy-Terminus of Angiotensin II Type 1A and 1B Receptors. Clinical Experimental Pharmacology and Physiology 32:936-943, 2005. [Abstract]

Hoffmann, A. and D. R. Cool. Angiotensin II Receptor Types 1A, 1B, and 2 in Murine Neuroblastoma Neuro2a Cells. Journal of Receptors and Signal Transduction 23(1): 111 - 121, 2003. [Abstract]

Grundhoff, A.T., E. Kremmer, O. Tureci, A. Glieden, C. Gindorf, J. Atz, N. Mueller-Lantzsch, W. H. Schubach, F.A. Grässer. Characterization of DP103, a Novel DEAD box Protein That Binds to the Epstein-Barr Virus Nuclear Proteins EBNA2 and EBNA3C. J. Biol. Chem. Jul 2: 247 (27): 19136-44, 1999. [Abstract]